Search Within

Andrew D Seidman

  1. "Biostatistics Service"
Formats
  1. Journal Article (37)
  2. Meeting Abstract (34)
  3. Research Letter (1)
Groups
  1. Biostatistics Service (72)
  2. Breast Medicine Service (72)
  3. Department of Medicine (72)
  4. Epidemiology and Biostatistics (72)
  5. Solid Tumor Oncology Division (72)
  6. Survivorship Research (55)

More Groups

People
  1. Clifford Hudis (39)
  2. Larry Norton (35)
  3. Sujata Patil (30)
  4. Katherine Panageas (23)
  5. Monica Fornier (20)
  6. Gabriella D'Andrea-Carlino (19)

More People

Years
  1. 2025 (2)
  2. 2024 (4)
  3. 2023 (3)
  4. 2022 (5)
  5. 2021 (3)
  6. 2020 (1)

More Years

Publications
  1. Journal of Clinical Oncology (20)
  2. Breast Cancer Research and Treatment (8)
  3. Clinical Cancer Research (7)
  4. International Journal of Radiation Oncology, Biology, Physics (6)
  5. Cancer Research (5)
  6. Clinical Breast Cancer (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (20)
  2. American Association for Cancer Research (13)
  3. Elsevier Inc. (13)
  4. Springer (8)
  5. Oxford University Press (6)
  6. Nature Publishing Group (4)

More Publishers

Results (72)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments
    Journal Article

    Dang, C. T.; Dannenberg, A. J.; Subbaramaiah, K.; Dickler, M. N.; Moasser, M. M.; Seidman, A. D.; D'Andrea, G. M.; Theodoulou, M.; Panageas, K. S.; Norton, L.; more...
    Clinical Cancer Research (2004)

    Fulltext@MSK | Save
  • Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer
    Journal Article

    Dang, C. T.; D'Andrea, G. M.; Moynahan, M. E.; Dickler, M. N.; Seidman, A. D.; Fornier, M.; Robson, M. E.; Theodoulou, M.; Lake, D.; Currie, V. E.; more...
    Clinical Cancer Research (2004)

    Fulltext@MSK | Save
  • Phosphorylated/activated HER2 (P-HER2) as a marker of clinical resistance to single agent taxane chemotherapy for meta-static breast cancer (MBC)
    Meeting Abstract

    Modi, S.; DiGiovanna, M. P.; Lu, Z.; Moskowitz, C.; Panageas, K. S.; Van Poznak, C.; Hudis, C. A.; Norton, L.; Tan, L.; Stern, D. F.; more...
    Proceedings of the American Association for Cancer Research Annual Meeting (2003)

    Fulltext@MSK | Save
  • Serum creatinine (Cr) values in patients with metastatic breast cancer (MBC) treated with pamidronate (PAM) administered as an intravenous 1 hour infusion (1 h)
    Meeting Abstract

    Van Poznak, C.; Ben-Porat, L.; Panageas, K.; Leone, D.; Seidman, A.; Hudis, C.
    Bone (2002)

    Fulltext@MSK | Save
  • Serum HER2 extracellular domain (ECD) correlates with HER2 status by immunohistochemistry (IHC) and fluorescent in-situ hybridization (FISH) in metastatic breast cancer (MBC) patients (pts) treated with weekly (W) trastuzumab (H) and paclitaxel (T)
    Meeting Abstract

    Fornier, M. N.; Seidman, A. D.; Schwartz, M. K.; Panageas, K. S.; Norton, L.; Hudis, C. A.
    Breast Cancer Research and Treatment (2002)

    Fulltext@MSK | Save
  • Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer
    Journal Article

    Van Poznak, C.; Tan, L.; Panageas, K. S.; Arroyo, C. D.; Hudis, C.; Norton, L.; Seidman, A. D.
    Journal of Clinical Oncology (2002)

    Fulltext@MSK | Save
  • Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer
    Journal Article

    Modi, S.; Panageas, K. S.; Duck, E. T.; Bach, A.; Weinstock, N.; Dougherty, J.; Cramer, L.; Hudis, C.; Norton, L.; Seidman, A.
    Journal of Clinical Oncology (2002)

    Fulltext@MSK | Save
  • Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
    Journal Article

    Seidman, A. D.; Fornier, M. N.; Esteva, F. J.; Tan, L.; Kaptain, S.; Bach, A.; Panageas, K. S.; Arroyo, C.; Valero, V.; Currie, V.; more...
    Journal of Clinical Oncology (2001)

    Fulltext@MSK | Save
  • Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma
    Journal Article

    Fornier, M. N.; Seidman, A. D.; Theodoulou, M.; Moynahan, M. E.; Currie, V.; Moasser, M.; Sklarin, N.; Gilewski, T.; D'Andrea, G.; Salvaggio, R.; more...
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save
  • Clinical-pathologic assessment of the clinical sensitivity to single agent taxane (T) therapy for metastatic breast cancer (MBC)
    Meeting Abstract

    Van Poznak, C.; Tan, L.; Panageas, K.; Arroyo, C.; Hudis, C.; Norton, L.; Seidman, A. D.
    Breast Cancer Research and Treatment (2000)

    Fulltext@MSK | Save